Skip to content

UZ Brussel HRMC Registry of Brugada Syndrome

UZ Brussel Heart Rhythm Management Center Monocentric Registry of Brugada Syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05283759
Acronym
HRMCBrS
Enrollment
2000
Registered
2022-03-17
Start date
1992-01-01
Completion date
2032-01-01
Last updated
2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brugada Syndrome

Brief summary

The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome at UZ Brussel hospital (UZB).

Detailed description

The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome. These includes: 1. demographical data: age, sex 2. antropometric data: height, weight, BMI 3. clinical data: comorbidities, arrhythmias, PM or ICD implantation, therapy 3\) data on the families: number of family members, sudden death history. 4) data on the genetics 5) data on: ECG, echocardiography, CT scan, MRI of heart, MRI of brain, ECG imaging, 3D electroanatomical mapping and ablation

Interventions

OTHERNo intervention because it is a patient registry

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Brugada syndrome diagnosis

Exclusion criteria

* Other diagnosis different from Brugada syndrome

Design outcomes

Primary

MeasureTime frameDescription
Ventricular arrhythmiasthrough study completion, an average of 10 yearComposite of: sudden cardiac death, aborted sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, ICD appropriate therapy
Atrial fibrillationthrough study completion, an average of 10 yearAtrial fibrillation occurrence
Death for any causethrough study completion, an average of 10 yearDeath for any cause
Cardiovascular deaththrough study completion, an average of 10 yearDeath for cardiovascular cause
Genetic mutationsBaselineGenetic mutations (pathogenic and variant of unknown significance) associated with Brugada syndrome. Wide gene panel with next generation sequencing will be used: Roche SeqCap® EZ Human Exome Probes v3.0 for BrS.

Countries

Belgium

Contacts

Primary ContactCarlo de Asmundis, MD, PhD
hrmc@uzbrussel.be+32024763704

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026